September 21, 2015
Cadwalader is pleased to announce it represented Credit Suisse in a transaction for which Credit Suisse was the sole structuring and financial advisor to AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) in the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil sublingual tablet system) in the European Union by its commercial partner Grunenthal GmbH. AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that gross proceeds from the sale are $65 million.
The Cadwalader team included Christopher Cox, Corporate; Ira Schacter and Steve Lenkowsky, Capital Markets; Dorothy Auth, Intellectual Property; and David Miller, Tax.
our latest insights on the impact of COVID-19 to help you navigate this unprecedented environment.
Patrick Quinn and Ruth Merisier discuss the legal profession, working at Cadwalader, and more.
Selections to the Lawdragon 500 are limited to no more than 500 lawyers in the country.
Our latest podcast covers the legacy of the “Car Wash” investigation and how Brazil fits into the global landscape of white-collar crime enforcement.